Q2 saw 3% organic growth and adjusted EPS of $1.41, both above guidance, driven by strong diagnostics and AI-related demand. Full-year outlook was raised for organic growth, margins, and EPS, with robust backlog and new product launches positioning the company for continued momentum.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.